Esser, Regina

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 709

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients

Ciardiello, F., Adams, R., Tabernero, J., Seufferlein, T., Taieb, J., Moiseyenko, V., Ma, B., Lopez, G., Vansteenkiste, J. F., Esser, R., et al. (2016) · The Oncologist

Patient-Provider Communication in HealthcareCancer Genomics and Diagnostics

Cited by 53

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer

Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 47

Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).

Tabernero, J., Van Cutsem, E., Prausová, J., Isambert, N., Neuzillet, C., Siena, S., Pietrantonio, F., Falk, S., Wainberg, Z. A., Raghav, K. P. S., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 4